N-methyl-4-(pyrrolidin-1-yl)butan-1-amine | 153905-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-methyl-4-(pyrrolidin-1-yl)butan-1-amine
• 英文别名: Methyl[4-(pyrrolidin-1-yl)butyl]amine；N-methyl-4-pyrrolidin-1-ylbutan-1-amine
• CAS: 153905-93-2
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: MFOCREKBYFNQTJ-UHFFFAOYSA-N

物化性质

• 沸点：
  217.8±8.0 °C(Predicted)
• 密度：
  0.889±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-4-(pyrrolidin-1-yl)butan-1-amine 在 lithium aluminium tetrahydride 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 N,N'-dimethyl-N'-(4-pyrrolidin-1-ylbutyl)butane-1,4-diamine
  参考文献：
  名称：

  A new approach to the design of .sigma.-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine-related polyamines at .sigma.-1 and .sigma.-2 receptor subtypes

  摘要：

  A series of polyamines based on the high affinity sigma receptor ligand N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamine (3) were developed and evaluated for their binding characteristics at sigma-1 and sigma-2 receptor subtypes. The data indicated that a considerable degree of structural variation is possible while still retaining nanomolar affinity at a receptors; As the structure of the polyamines was varied, their binding at sigma-1 and sigma-2 subtypes showed quite different and in some cases opposite trends, supporting the belief that these are pharmacologically distinct entities. Polyamines containing two nitrogen atoms showed optimal binding at both sigma-1 and sigma-2 receptor subtypes. Although additional nitrogen atoms resulted in decreased affinity at sigma-1 and sigma-2 subtypes, an increase in selectivity for sigma-2 subtypes was evident; the parent 3 showed greater selectivity for sigma-1 subtypes. Internitrogen spacings had a large effect on binding affinity and subtype selectivity. For example, the difference between N-[3-(1-pyrrolidinyl)propyl]-N'-(3,4-dichlorobenzyl)-N,N'-dimethylethylenediamine (8) [K-i = 29.9 nM at sigma-1 receptor and 18.3 nM at alpha-2 receptor] to N-[3-(1-pyrrolidinyl)propyl]-N'-(3,4-dichlorobenzyl)-N/N'-dimethylethylenedi- amine (10) [K-i = 1.49 nM at sigma-1 receptor and 12.1 nM at sigma-2 receptor] illustrates the importance of internitrogen spacing. Triamines 11 and 13 [K-i(sigma-2)/K-i(sigma-1) = 0.19 and 0.10, respectively] containing the N-N-N-Ar spacings 3-3-2 and 4-4-2, proved to be the most sigma-2 subtype selective of the 15 polyamines examined in this study. The N-N-N spacings appear to be an important factor in their sigma-2 subtype selectivity. These compounds will serve as templates in the design of still further sigma-2 subtype selective ligands. The pyrrolidine ring (present in most of the polyamines tested in this series) proved to be an important recognition site for a receptor binding activity. Furthermore, alkyl substitution also appears to be important since the stripped down polyamines N-[2-(3,4-dichlorophenyl)ethyl]ethylenediamine (15) and N-1-[2-(3,4-dichlorophenyl)ethyl] diethylenetriamine (16) exhibited relatively low binding affinity.

  DOI：

  10.1021/jm00028a016
• 作为产物：
  描述：

  4-吡咯烷丁胺 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 N-methyl-4-(pyrrolidin-1-yl)butan-1-amine
  参考文献：
  名称：

  Structure–activity relationship studies of SETD8 inhibitors

  摘要：

  对第一个底物竞争性SETD8抑制剂的全面SAR研究揭示了有趣的SAR趋势和新颖的类似物。

  DOI：

  10.1039/c4md00317a

文献信息

• Novel pyridine derivative and pyrimidine derivative
  申请人：Matsushima Tomohiro

  公开号：US20050277652A1

  公开（公告）日：2005-12-15

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents C 1-6 alkyl or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents C 1-6 alkyl or the like; V 1 represents oxygen or the like; V 2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]

  以下化合物的分子式，其盐或前述水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抑制血管生成活性和抑制癌转移活性。 [R 1 代表C 1-6 烷基或类似物；R 2 和R 3 代表氢；R 4 ，R 5 ，R 6 和R 7 可以相同也可以不同，每个代表氢、卤素、C 1-6 烷基或类似物；R 8 代表氢或类似物；R 9 代表C 1-6 烷基或类似物；V 1 代表氧或类似物；V 2 代表氧或硫；W代表—NH—或类似物；X代表—CH═、氮或类似物；Y代表氧或类似物。]
• [EN] COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS<br/>[FR] COMPOSÉS ET LEUR UTILISATION DANS L'EXPANSION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES ET/OU CELLULES PROGÉNITRICES HÉMATOPOÏÉTIQUES
  申请人：UNIV MONTREAL

  公开号：WO2015161373A1

  公开（公告）日：2015-10-29

  Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations. Particularly, the hematopoietic cells are human cells. The compounds are also useful in the medical treatment of hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immune-deficient disease in a subject.

  本文提供并描述了一般式化合物、盐或其前药。这些化合物对于扩增造血干细胞和/或造血祖细胞群体是有用的。特别地，这些造血细胞是人类细胞。这些化合物还可用于治疗受试者的造血障碍/恶性肿瘤、自身免疫疾病和/或遗传性免疫缺陷疾病。
• Novel pyridine Derivative and Pyrimidine Derivative (1)
  申请人：Matsushima Tomohiro

  公开号：US20070270421A1

  公开（公告）日：2007-11-22

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents C 1-6 alkyl or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents C 1-6 alkyl or the like; V 1 represents oxygen or the like; V 2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]

  以下化合物的公式，其盐或水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性，抑制血管生成活性和癌症转移抑制活性。 [其中，R1代表C1-6烷基或类似物; R2和R3代表氢; R4，R5，R6和R7可能相同或不同，每个代表氢，卤素，C1-6烷基或类似物; R8代表氢或类似物; R9代表C1-6烷基或类似物; V1代表氧或类似物; V2代表氧或硫; W代表—NH—或类似物; X代表—CH═、氮或类似物; Y代表氧或类似物。]
• NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2)
  申请人：Eisai Co., Ltd.

  公开号：EP1719763A1

  公开（公告）日：2006-11-08

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents C1-6 alkyl or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9b represents a 3- to 10-memberd non-aromatic heterocyclic group or the like; V1 represents oxygen or the like; V2 represents oxygen or sulfur; W represents -CH2- or the like; X represents -CH=, nitrogen or the like; and Y represents oxygen or the like.]

  下式代表的化合物、其盐或前述化合物的水合物具有极佳的肝细胞生长因子受体（HGFR）抑制活性，并具有抗肿瘤活性、血管生成抑制活性和癌症转移抑制活性。 [R1 代表 C1-6 烷基或类似物；R2 和 R3 代表氢； R4、R5、R6 和 R7 可以相同或不同，各自代表氢、卤素、C1-6 烷基或类似物；R8 代表氢或类似物；R9b 代表 3 至 10 个成员的非芳香杂环基团或类似物；V1 代表氧或类似物；V2 代表氧或硫；W 代表 -CH2- 或类似物；X 代表 -CH=、氮或类似物；Y 代表氧或类似物。］
• FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS
  申请人：LifeArc

  公开号：EP3939981A1

  公开（公告）日：2022-01-19

  The present invention relates to compounds of formulae I and II, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

  本发明涉及式 I 和式 II 的化合物或其药学上可接受的盐或酯。 本发明的其他方面涉及所述化合物在治疗细胞生长、增殖和/或存活失控疾病、不适当的细胞免疫反应、不适当的细胞炎症反应或神经退行性疾病（优选牛磺酸病，更优选阿尔茨海默病）中的药物组合物和治疗用途。